Kimia Biosciences Limited, a pharmaceutical company, has announced a significant change in its leadership. Mr. Prasad Raju (Ramakrishnavara Prasada Raju Mantena), a director of the company, has resigned from his position effective November 12, 2025. The resignation comes as a result of medical advice and personal well-being concerns.

Key Details of the Resignation

Company's Response

Kimia Biosciences Limited has accepted Mr. Raju's resignation and relieved him from his duties on November 12, 2025. The company made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director's Statement

In his resignation letter, Mr. Raju expressed his gratitude to the Board and his colleagues. He stated, "It has been an honour to serve and contribute to the growth of Kimia Biosciences Limited." Mr. Raju also assured his full support in ensuring a smooth transition of duties and responsibilities.

Impact and Next Steps

The company has not provided information on a successor but has confirmed that there are no material reasons for the resignation other than those mentioned in Mr. Raju's letter. The Board will likely begin the process of finding a suitable replacement to ensure continuity in the company's operations and strategic direction.

This change in directorship comes at a time when pharmaceutical companies are facing increasing challenges and opportunities in the global market. Stakeholders will be watching closely to see how Kimia Biosciences navigates this transition and continues to pursue its business objectives.

As per regulatory requirements, Kimia Biosciences Limited has duly informed the BSE Limited of this development, maintaining transparency with its investors and the market at large.

Kimia Biosciences Limited, an Indian pharmaceutical company, has released its unaudited standalone financial results for the first quarter ended June 30, 2025, showing a mixed performance with year-over-year declines but sequential improvements.

Financial Highlights

Performance Analysis

Kimia Biosciences demonstrated resilience in a challenging market environment. While the company experienced a slight decline in total income and net profit compared to the same quarter last year, it showed significant sequential growth, indicating a potential recovery trend.

The quarter-over-quarter improvements across all key financial metrics suggest that the company's strategies may be gaining traction, despite the year-over-year pressures.

Regulatory Compliance

In accordance with regulatory requirements, Kimia Biosciences has published its unaudited standalone financial results in both English and Hindi newspapers. This transparency measure ensures that stakeholders have access to the company's financial information in multiple languages.

Looking Ahead

As Kimia Biosciences navigates the dynamic pharmaceutical landscape, investors and analysts will likely keep a close eye on whether the company can maintain its sequential growth momentum and address the year-over-year declines in subsequent quarters.

The pharmaceutical sector continues to be a critical industry, and Kimia Biosciences' performance in the coming quarters will be instrumental in determining its position within the market.